导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.92% | 2449/4773 |
| 近一周 | -2.85% | 3260/5462 |
| 近一月 | -7.02% | 3708/5421 |
| 近一季 | -13.30% | 3980/5209 |
| 近半年 | -5.79% | 2951/4920 |
| 近一年 | 2.86% | 2036/4366 |
| 近两年 | 64.91% | 1075/2954 |
| 近三年 | 32.78% | 944/2253 |
| 成立以来 | 48.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.54% 1845/4961 |
19.81% 1274/5312 |
- - |
- - |
| 2025 | 29.38% 1404/4813 |
0.74% 1778/3635 |
0.35% 2686/4076 |
27.95% 1291/4524 |
0.02% 2285/4813 |
| 2024 | 10.19% 1428/3463 |
-1.45% 1226/2808 |
-4.64% 1534/3014 |
18.20% 1043/3129 |
-0.81% 1523/3463 |
| 2023 | -12.55% 1487/2656 |
5.93% 742/2280 |
-5.10% 1369/2385 |
-7.77% 1621/2515 |
-5.68% 1455/2655 |
| 2022 | -24.46% 1219/2207 |
-17.78% 1260/1919 |
6.68% 633/2016 |
-15.51% 1307/2113 |
1.93% 1082/2208 |
| 2021 | 4.68% 569/1822 |
-4.36% 858/1255 |
10.57% 451/1330 |
-4.55% 719/1466 |
3.70% 401/1822 |
| 2020 | 40.08% 318/1250 |
-4.27% 349/1028 |
20.07% 286/1067 |
9.03% 681/1164 |
11.78% 520/1184 |
| 2019 | 42.51% 212/1092 |
34.53% 107/739 |
-6.38% 501/788 |
3.12% 268/850 |
9.74% 201/918 |
| 2018 | -32.43% 532/834 |
- - |
-12.61% 400/631 |
-9.60% 523/660 |
-13.08% 508/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方深证成份ETF联接C VS. 长安沪深300非周期A(740101) |